



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/053,329	11/09/2001	Michael Baudino	11738.00050	4048
27581	7590	10/12/2006	EXAMINER	
MEDTRONIC, INC. 710 MEDTRONIC PARK MINNEAPOLIS, MN 55432-9924			WITCZAK, CATHERINE	
			ART UNIT	PAPER NUMBER
			3767	

DATE MAILED: 10/12/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/053,329	BAUDINO ET AL.
	Examiner	Art Unit
	Catherine N. Witczak	3767

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 18 August 2006.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-80, 82-86, 89-107 and 110-141 is/are pending in the application.
- 4a) Of the above claim(s) 1-79 and 110-141 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 80, 82-86, and 89-107 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) Notice of Informal Patent Application
- 6) Other: _____

DETAILED ACTION***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

1. Claims 80 rejected under 35 U.S.C. 103(a) as being unpatentable over Howard, III (US 6,129,685) as modified by Imran (US 5,964,796).

Claims 80, 82, 83, 85, 86, 89, 103, 106, and 107: Howard discloses in Figure 25 an implantable delivery system for treating a neurological disorder comprising a cannula (137) having a central lumen, a first and second catheters (141) insertable within the cannula, and a therapy delivery device (147) storing a liquid agents and having a replenishment port refillable by a hypodermic needle (column 42, lines 52-65).

Howard discloses the claimed invention except for the cannula having a plurality of opening provided neat the distal end for directing the catheter away from the central axis of the cannula. Imran teaches in Figure 7 it is known to use a cannula having a plurality of openings through which catheters extend. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the system as taught by Howard with a cannula having a plurality of opening through which catheters extend, since such a modification would provide a larger coverage area of where drug is delivered.

Claims 84, 90, and 102 are rejected under 35 U.S.C. 103(a) as being unpatentable over HOWARD, III and Imran as applied to claims 80 and 103 above and further in view of ELSBERRY et al. (US Patent No.

Art Unit: 3767

5,711,316). Howard also discloses that the drug delivery pump can be controlled by a processor at a variable rate (col. 42, 11.55-63). Howard and Imran do not disclose a sensor indicative of treated condition. Elsberry discloses a sensor indicative of treated condition to facilitate the delivery of the correct dosing of drug for treating a patient. It would have been obvious to one of ordinary skill in the art at the time of the invention to use the teachings of Elsberry in the system of Howard to appropriately administer medication to treat a patient.

Claims 91, 92, 95, 96, 97, 98, 99, 100, 101, 104, and 105 are rejected under 35 U.S.C. 103(a) as being unpatentable over HOWARD, III and Imran as applied to claims 80 and 103 above and further in view of COSGROVE, Jr. et al. (US Patent No. 4,533,346). Howard, III and Imran disclose the claimed invention except for reading a parameter and level of signal to control liquid infusion rate, adjusting rate, and exceeding a maximum setting value results in indicative output. Cosgrove discloses a interfaced control scheme used in the prior art that adjusts a setting of infusion rates based on, multiple analog signal levels based on the drug or physiological parameters (col. 3, line 55 - col. 5, line 62). It would have been obvious to one of ordinary skill in the art at the time of the invention to use the teachings of Cosgrove in the system of Howard, III and Imran in order to achieve precise control of drug delivery to a patient. It would have been obvious to one of ordinary skill in the art at the time of the invention to use alarms and telemetry in the process control scheme in order to alert the user when maximum or dangerous levels are exceeded to provide a better level of control and to use telemetry to enable remote control settings to be established.

Claim 94 is rejected under 35 U.S.C. 103(a) as being unpatentable over HOWARD, III and Imran and COSGROVE, Jr. et al. as applied to claim 92 above further in view of ABBOTT et al. (US Patent No. Re. 36386). Howard, III, Imran, and Cosgrove disclose the claimed invention except for resetting a timer

Art Unit: 3767

when a parameter is changed. Abbott teaches resetting a timer when a parameter associated the flowrate is changed. (see para. (d) of claim 31). It would have been obvious to one of ordinary skill in the art at the time of the invention to use the teachings of Abbott in the system of Howard, III, Imran, and Cosgrove in order to obtain additional flow information concerning drug delivery parameters to more precisely control the drug delivery profile to the patient.

Response to Arguments

1. Applicant's arguments, see Response, filed 8/18/2006, with respect to the drawings, the 112th rejections, and the specification have been fully considered and are persuasive. The objection of the drawings, the 112th rejections, and the specification have been withdrawn.
2. Applicant's arguments with respect to claims 80, 82-86, and 89-107 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Art Unit: 3767

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Catherine N. Witczak whose telephone number is (571) 272-7179. The examiner can normally be reached on Monday through Friday, 8-5 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kevin Sirmons can be reached on (571) 272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

cw

 10/8/06

KEVIN C. SIRMONS
SUPERVISORY PATENT EXAMINER

